Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly



Status:Completed
Conditions:Skin Cancer, Endocrine
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:18 - Any
Updated:1/17/2019
Start Date:May 2000
End Date:January 2003

Use our guide to learn which trials are right for you!

Phase II, Multicentre, Randomized, Double-blind Study in Acromegalic Patients Evaluating the Efficacy and Safety of a Single Deep Subcutaneous Administration of Lanreotide Autogel (60, 90 or 120mg) Versus Placebo Followed by a Single Blind Fixed Dose Phase Evaluating the Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Profile of Multiple Deep Subcutaneous Administrations of Lanreotide Autogel (60, 90 & 120mg) Ending in Open Label Dose Titration Phase.

The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo
after a single injection. Effectiveness and safety were then also assessed following four
fixed-dose injections and after one year of treatment given at titrated doses.


Inclusion Criteria:

- documentation of a diagnosis of active acromegaly based on either of the following
definitions:

1. the patient has never received somatostatin analog nor dopaminergic agonist or
had previously received this medication but had stopped more than 3 months before
visit 1 and had a mean growth hormone (GH)level >5ng/mL at visit 1; or

2. the patient was receiving treatment with a somatostatin analog (other than
lanreotide autogel) or a dopaminergic agonist at visit 1, had a mean GH >3ng/mL
at visit 2 (or visit 2a) and had at least a 100% increase in mean GH levels
between visit 1 and visit 2 (or visit 2a)

Exclusion Criteria:

- receipt of radiotherapy for acromegaly within 3 years

- pituitary surgery within 3 months prior to visit 1

- prior receipt of lanreotide autogel or GH antagonist

- anticipated need for pituitary surgery (adenomectomy) or radiotherapy during the study
period

- known hypersensitivity to any of the test materials or related compounds

- clinically significant renal or hepatic abnormalities
We found this trial at
12
sites
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
733 North Broadway
Baltimore, Maryland 21205
(410) 955-3182
Johns Hopkins University School of Medicine Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35213
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Brno,
Click here to add this to my saved trials
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90048
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Portland, Oregon 97227
?
mi
from
Portland, OR
Click here to add this to my saved trials